| pubmed-article:6386801 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C0033692 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C1513095 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C0017968 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C0033689 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C0444669 | lld:lifeskim |
| pubmed-article:6386801 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:6386801 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:6386801 | pubmed:dateCreated | 1984-11-30 | lld:pubmed |
| pubmed-article:6386801 | pubmed:abstractText | Monoclonal antibody (Mab) 9.2.27 was utilized in a combination of biosynthetic and biochemical investigations as an immunological probe for the study of chondroitin sulfate proteoglycans (CSP) in human melanoma cells. Pulse-chase and long-term intrinsic labeling immunoprecipitation experiments combined with the biosynthetic inhibitors monensin, cycloheximide, and paranitrophenol-beta-D-xyloside all suggest that Mab 9.2.27 recognizes a set of glycoprotein molecules ranging to a 250-kDa glycoprotein which serves as the core glycoprotein for CSP in human melanoma cells. Peptide maps comparing the 250-kDa and CSP molecule verify that the 250-kDa glycoprotein is the CSP core protein in human melanoma cells. Further studies document that the CSP released by melanoma cells and recognized by Mab 9.2.27 contains (2-acetamido-2-deoxy-3-O-(beta-D-gluco-4-enepyranosyluronic acid)-beta-4-O-sulfo-D-galactose and 2-acetamido-2-deoxy-3-O-(beta-D-gluco-4-enepyranosyluronic acid)-beta-6-O-sulfo-D-galactose saccharides and this CSP can interact with hyaluronic acid-Sepharose. Topographical studies indicate that this CSP has pericellular punctuated distribution on the melanoma cell surface and may play a role in cell-substrate interactions in the biology of metastatic human melanoma. | lld:pubmed |
| pubmed-article:6386801 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6386801 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6386801 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6386801 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:6386801 | pubmed:issn | 0021-9258 | lld:pubmed |
| pubmed-article:6386801 | pubmed:author | pubmed-author:ReisfeldR ARA | lld:pubmed |
| pubmed-article:6386801 | pubmed:author | pubmed-author:WalkerL ELE | lld:pubmed |
| pubmed-article:6386801 | pubmed:author | pubmed-author:BumolT FTF | lld:pubmed |
| pubmed-article:6386801 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6386801 | pubmed:day | 25 | lld:pubmed |
| pubmed-article:6386801 | pubmed:volume | 259 | lld:pubmed |
| pubmed-article:6386801 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6386801 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6386801 | pubmed:pagination | 12733-41 | lld:pubmed |
| pubmed-article:6386801 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:meshHeading | pubmed-meshheading:6386801-... | lld:pubmed |
| pubmed-article:6386801 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6386801 | pubmed:articleTitle | Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. | lld:pubmed |
| pubmed-article:6386801 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6386801 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6386801 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6386801 | lld:pubmed |
